CONCLUSION
CSII pumps may offer significant benefits to diabetic patients, compared with their current MDI regimen. These include reduction in A1C without increases in hypoglycemia, greater flexibility, improved quality of life—and, especially when used in conjunction with continuous glucose monitoring, reduction in glycemic variability. Patients and providers must bear in mind, however, that the pump is a tool, not a substitute for what guarantees success in diabetes management—namely, attention to meal planning, carbohydrate-counting, frequent blood sugar monitoring, competent sick day management, regular exercise, and target blood sugar and A1C goals. The patient most likely to benefit from insulin pump use is one with the motivation to make the lifestyle changes that effective therapy requires.
REFERENCES
1. General Hospital and Personal Use Medical Devices Panel Meeting—March 5, 2010. www .fda.gov/downloads/AdvisoryCommittees/Com mitteesMeetingMaterials/MedicalDevices/
MedicalDevicesAdvisoryCommittee/General HospitalandPersonalUseDevicesPanel/
UCM203749.pdf. Accessed October 21, 2011.
2. Fabiato K, Buse J, Duclos M, et al. Clinical experience with continuous glucose monitoring in adults. Diabetes Technol Ther. 2009;11 suppl 1:S93-S103.
3. Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011; 34(4):795-800
4. Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther. 2010;12(8):627-633.
5. Skladany MJ, Miller M, Guthermann JS, Ludwig CR. Patch-pump technology to manage type 2 diabetes mellitus: hurdles to market acceptance. J Diabetes Sci Technol. 2008;2(6): 1147-1150.
6. Lynch PM, Riedel AA, Samant N, et al. Resource utilization with insulin pump therapy for type 2 diabetes mellitus. Am J Manag Care. 2010;16(12):892-896.
7. Nielsen S, Kain D, Szudzik E, et al. Use of continuous subcutaneous insulin infusion pump in patients with type 2 diabetes mellitus. Diabetes Educ. 2005;31(6):843-848.
8. Scheiner G, Sobel RJ, Smith DE, et al. Insulin pump therapy: guidelines for successful outcomes. Diabetes Educ. 2009;35 suppl 2:29S-41S.
9. Unger J. Insulin pump therapy. In: Unger J. Diabetes Management in Primary Care. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:265-320.
10. Hagedorn HC. Modifications of insulin. Physician’s Bull. 1947;12(5):26-33.
11. Salemyr J, Bang P, Örtqvist E. Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study. Pediatr Diabetes. 2011;12(5):501-505.
12. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia. 1983;24(5): 326-329.
13. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984; 7(2):188-199.
14. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c–independent risk factor for diabetic complications. JAMA. 2006;295(14): 1707-1708.
15. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31 suppl 1:S12-S54.
16. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocrine Pract. 2011;17(suppl 2):1-53.
17. Kaufman F. Insulin treatment. In: Kaufman F, ed. Medical Management of Type 1 Diabetes. 5th ed. Alexandria, VA: American Diabetes Association; 2008:57-82.
18. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-183.
19. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240-1244.
20. Diabetes Research in Children Network (DirecNet) Study Group. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care. 2006;29(10):2200-2204.
21. Maran A, Pavan P, Bonsembiante B, et al. Continuous glucose monitoring reveals delayed nocturnal hypoglycemia after intermittent high-intensity exercise in nontrained patients with type 1 diabetes. Diabetes Technol Ther. 2010; 12(10):763-768.
22. Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14(9):1095-1101.
23. Glycemic Index Foundation, Sydney University Glycemic Index Research Service (SUGiRS). GI testing and research. www.glycemicindex
.com. Accessed October 21, 2011.
24. Pankowska E, Błazik M. Bolus calculator with nutrition database software, a new concept of prandial insulin programming for pump users.
J Diabetes Sci Technol. 2010;4(3):571-576.
25. Davis SN, Horton ES, Battelino T, et al. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010;12(4):249-255.
26. Buse JB, Dailey G, Ahmann AA, et al. Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol Ther. 2011;13(6):601-606.
27. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: results from the 6-month continuation phase. Diabetes Care. 2011 Sep 20. Epub ahead of print.